RodrigoOtavio BoffMaegawaMD

Oncology • Brewer, ME

Hematologic Oncology

Physician

Join to view full profile

Dr. Maegawa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maegawa's full profile

Already have an account?

Office
33 Whiting Hill Road
Eastern Maine Medical Center
Brewer, ME 04412
Phone+1 207-973-7478

Fax+1 207-973-7807

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2008 - 2011
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2005 - 2008
Federal University of Parana Faculty of MedicineClass of 2005

Certifications & Licensure

ME State Medical License 2012 - 2026
CA State Medical License 2011 - 2025
NJ State Medical License 2020 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

3 citations
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Jerald P Radich, Matthew Wall, Susan Branford, Catarina D Campbell, Shalini Chaturvedi
Haematologica. 2023-06-01
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.
Ehab Atallah, Lovneet Saini, Rodrigo Maegawa, Tanvi Rajput, Regina Corbin
Therapeutic Advances in Hematology. 2023-01-01
1 citations
Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Pers...
Ehab L Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin
Journal of Health Economics and Outcomes Research. 2022-01-01

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Maine Patients and Researchers Fighting Cancer – Part 1February 2nd, 2017
Maine Patients and Researchers Fighting Cancer – Part 2February 2nd, 2017